REGENXBIO, UPenn settle patent suit with Sarepta over ELEVIDYSSep 23Partnershipdelandistrogene moxeparvovecREGENXBIO Inc.
FDA places clinical hold on REGENXBIO's RGX-121 for Hunter SyndromeAug 24Regulatory decisionREGENXBIO Inc.
Regenxbio reports Q2 2026 results, cites Duchenne trial win and new AbbVie fundsAug 6Quarterly updateAbbVieREGENXBIO Inc.
REGENXBIO closes $100 million offering after underwriters exercise full overallotmentJul 20FinancingREGENXBIO Inc.
REGENXBIO doses first patient in Phase IIb/III diabetic retinopathy trial, triggers $100M paymentJun 29Clinical readoutREGENXBIO Inc.
Sign in